Management Team
Junyuan Jerry Wang, Ph.D.
CEO & Co-Founder
Dr. Junyuan (Jerry) Wang is Chief Executive Officer & Co-Founder at AnHeart Therapeutics. He has more than 20 years of leadership experience in global clinical development and medical research, having previously worked at Merck Serono, BMS, Wyeth/Pfizer, The Medicines Company, and Merck & Co. He has broad drug development experience across multiple therapeutic areas including oncology, cardiovascular, neuroscience, and immunology. He has made key contributions to successful NDA of Bosulif and Eliquis, and the latter became multi-billion blockbuster drug. He has extensive experience with global health authorities including FDA, EMA, PMDA and NMPA. He also served in leadership roles for professional societies and on the programming committee of leading scientific conferences. Dr. Wang earned his B.S. from the University of Science and Technology of China and Ph.D. in Statistics from Iowa State of University.
Bing Yan, M.D., MBA
Co-Founder & Chief Medical Officer
Dr. Bing Yan is Chief Medical Officer and Co-Founder at AnHeart Therapeutics. He was trained as a medical doctor and has more than 20 years of pharmaceutical industry experience in novel drug and vaccine development, regulatory interactions, and post-approval activities. Prior to joining AnHeart, Dr. Yan was the Global Vice-President and Head of Asia Pacific Clinical Research at Pfizer. He has deep experience across multiple therapeutic areas including neuroscience, vaccines, anti-infectives, transplant, oncology, men’s/women’s health and metabolic disorders. He played a significant leadership role in bringing Prevnar13, Xalkori, Lyrica, Enbrel, Pristiq, Effexor, and Xyntha new drug registrations in China and Japan. Dr. Yan holds a doctorate in clinical medicine from Shanghai JiaoTong University Medical School/Ruijin Hospital and conducted his post-doc fellowship at Johns Hopkins University School of Medicine and Eastern Virginia Medical School.
Lihua Zheng, J.D., Ph.D.
Co-Founder & Chief Strategy Officer
Dr. Lihua Zheng is Chief Strategy Officer and Co-Founder at AnHeart Therapeutics. Dr. Zheng leads corporate and financing strategy for the company. He led the successful in-licensing of three clinical-stage oncology assets from Daiichi Sankyo, and also established commercial partnerships with Innovent Biologics and NewG labs with upfront and milestone payments totaling approximately $200 million plus double-digit royalties, and raised more than $100 million in private venture financing. Dr. Zheng was previously a legal and business advisor for biopharma companies at a New York-based international law firm, before he founded a boutique law firm in New York City. He received his J.D. from Fordham University School of Law and a Ph.D. in Molecular and Human Genetics from Baylor College of Medicine. He obtained his Masters and Bachelors of Science degree from Fudan University. He is licensed to practice law in the State of New York.
Shuanglian Lian Li, M.D., Ph.D.
Senior Vice President and Chief Medical Officer (US)
Shuanglian (Lian) Li, M.D., Ph.D., is Senior Vice President and Chief Medical Officer (US) at AnHeart Therapeutics. In this role, Dr. Li will oversee and direct all U.S.-based clinical programs. Dr. Li is an accomplished clinical development physician with over 15 years of drug development experience from preclinical drug safety to late-stage drug development and post-marketing clinical research. Her clinical development expertise has specialized in precision medicine and adoptive cellular therapy.
Prior to joining AnHeart, Dr. Li was SVP, Clinical Development at Ansun Biopharma, where she led and drove the overall clinical development strategy of the company’s oncology pipeline and clinical development plan. She also led clinical and regulatory strategy as Head of Clinical Development at Skyline Therapeutics, a gene therapy company headquartered in Shanghai.
Dr. Li was also the Global Clinical Lead for mobocertinib, a first-in-class EGFR inhibitor that targeted EGFR exon 20 insertions, at Takeda Pharmaceuticals. Prior to its acquisition by Takeda, Dr. Li was Medical Director at ARIAD Pharmaceuticals and the medical lead for several oncology programs. Dr. Li has held various positions with increasing responsibilities at Biogen, Pfizer and Sugen.
Dr. Li received her Ph.D. in Pharmaceutical Sciences & Pharmacogenomics, from the University of California, San Francisco and an M.D. from Beijing Medical University. She also obtained an M.S. in Pharmacology & Toxicology from the University of Mississippi.
Edward Lang Jr.
Chief Business Officer
Ed brings more than 20 years of experience in the biotechnology industry and as Chief Business Officer oversees business development, communications and investor relations. He is also building AnHeart’s initial commercial capabilities. Ed has a deep knowledge of corporate strategy, a proven track record of raising capital, and extensive experience in launching cancer medicines.
Prior to joining AnHeart, Ed served as Chief Business Officer at Gyroscope Therapeutics, a global clinical-stage gene therapy company focused on eye disease, acquired by Novartis. Ed previously served as Vice President, Corporate Affairs at Juno Therapeutics, acquired by Celgene. Prior to Juno he spent 13 years at Genentech supporting the approval and launch of 15 new medicines.
Charlotte Arnold
Chief Corporate Affairs Officer
Charlotte is a seasoned corporate affairs executive with more than 25 years of experience in the healthcare industry, including biotech, pharma, and diagnostics. Most recently, Charlotte served as an executive at early-stage companies, where she played an integral role in setting and executing against corporate strategy, raising capital, developing corporate narrative and shaping company culture. She has built and led multiple corporate affairs functions, overseeing communications and investor relations, for both public and private companies.
Prior to joining AnHeart, Charlotte served as Senior Vice President, Corporate Affairs at Gyroscope Therapeutics, a global clinical-stage gene therapy company focused on eye disease, acquired by Novartis. She also previously served as Vice President, Corporate Affairs at GRAIL, Inc., acquired by Illumina, and Vice President, Corporate Communications and Investor Relations at Relypsa, Inc., acquired by Vifor Pharma. Prior to that she held several senior communications roles at Genentech over the span of almost 10 years.
Charlotte is a member of the Senior Advisory Board of the SF Bay Area Chapter of the Healthcare Businesswomen’s Association (HBA).
Fan Frank Fan, M.D., MBA
Senior Vice President & Head of Clinical Development Strategy
Dr. Frank Fan is Senior Vice President & Head of Clinical Development Strategy at AnHeart Therapeutics. He has nearly 25 years of working experience in clinical research and medical science functions for some global biopharmaceutical companies. Prior to joining AnHeart, Dr. Fan was the head of the medical and scientific service group, IQVIA Greater China. Dr. Fan has a Bachelor of Medicine degree from Capital Medical University and an MBA from Cranfield University.
Qinying Zhao, Ph.D.
Senior Vice President, Head of Global Clinical Pharmacology
Dr. Qinying Zhao is Senior Vice President and Head of Global Clinical Pharmacology at AnHeart Therapeutics. She has demonstrated strong leadership and decades of scientific expertise in global clinical pharmacology and clinical development. Dr. Zhao has extensive experience in clinical pharmacology strategy/execution and clinical development of innovative drugs, IND/NDA submissions, and interactions with global major regulatory agencies. Prior to AnHeart, she had worked as Global Clinical Pharmacology Lead at Janssen, Johnson & Johnson, and Pfizer. She had also served as a clinical pharmacology expert at Pfizer for maintenance and defense of marketed drugs in cardiovascular, pain, and inflammatory therapeutic areas. Dr. Zhao graduated from Fudan University. She earned her M. S. from China State Institute of Pharmaceutical Industry and Ph.D. from West Virginia University. She was a Postdoctoral Fellow at the University of Pennsylvania.
Hua Zheng, M.D., Ph.D.
Senior Vice President & Head of Global Regulatory Affairs
Dr. Hua Zheng is Senior Vice President & Head of Global Regulatory Affairs at AnHeart Therapeutics. He has more than 25 years of experience in regulatory strategy to advance global product development and registration. He has served in executive regulatory positions in a number of leadership roles (Vice President, Global Franchise Regulatory Lead, China Lead), and has held various positions at mulit-national companies such as Pfizer, J&J, Celgene, Amgen and biotech companies Advaxis and Sorrento. He has also served at the U.S. FDA. He has led and directed regulatory activities across all phases of global drug development, including US, China, Europe and Asia Pacific, in gaining approvals. Notably he served in critical leadership roles leading to market registrations for Yondelis®, Edurant®, Revlimid®, and Vidaza® in different countries with diverse regulatory challenges. Dr. Zheng holds a Ph.D. in Toxicology from University of California, Irvine. He has an M.Sc. in Pathology and completed his medical training from the former Beijing Medical University. He conducted postdoctoral research at National Cancer Institute, Kansas University Medical Center and University of California, San Diego.
Guilin Huang
Senior Vice President, Development
Guilin Huang is Senior Vice President, Development at AnHeart Therapeutics. She has more than 20 years of experience in global drug development with a focus on oncology and rare diseases, from pre-investigational new drug activities through regulatory reviews and commercialization.
Guilin joined AnHeart from Relay Therapeutics, where she served as Vice President and Head of Regulatory Affairs. Prior to Relay, she accumulated and enriched her drug development expertise as an accomplished regulatory strategist at Takeda Pharmaceuticals, ARIAD Pharmaceuticals, Chugai Pharmaceutical Co., and Vertex Pharmaceuticals.
Guilin holds a B.S. in pharmacy and Japanese from Shenyang Pharmaceutical University and earned her MBA in health sector management from Boston University. She also completed the Women Unlimited LEAD Program, a leadership development course for rising business leaders.
Amy Muse
Vice President, U.S. Commercial
Amy Muse is Vice President, U.S. Commercial at AnHeart Therapeutics. Amy is an accomplished commercial leader with more than 20 years of commercial experience in the pharmaceutical and biotech industry.
Prior to AnHeart, Amy served as Vice President, Marketing at Seres Therapeutics where she led the launch of the first FDA-approved oral microbiome therapeutic. Previously, she served as the U.S. Oncology Lung Cancer Franchise lead at Takeda where she led commercial efforts for Takeda’s precision therapies for EGFR-positive and ALK-positive non-small cell lung cancer in the United States. Prior to Takeda, Amy held several commercial roles, including marketing and sales positions, at Shire, Forest Laboratories, and Merck and Co.
Amy earned her bachelor’s degree in accounting from Ohio University and an MBA in marketing from the NYU Stern School of Business.
Board of Directors
Xiaohang Tony Tong, Ph.D.
Dr. Tony Tong is a Principal of Decheng Capital and has been with the firm since May 2014. He has an interest in diverse sectors within the China healthcare industry. He currently serves on the boards of AnHeart Therapeutics, CardiMED, Insight Lifetech and LYNK Pharmaceuticals.
Prior to joining Decheng Capital, Dr. Tong was a Vice President at Mingly China Growth Fund (MCGF), focusing on evaluating investment opportunities in the healthcare sector and serving on the boards of Yocaly (acquired by Lepu Medical), Family of Health (partially acquired by Sunshine Insurance), Sonicmed and Baifendian Technology. From 2009 to 2012, Dr. Tong was Senior Investment Associate at Yifang Ventures, a venture capital investment and asset management firm founded by Dr. Eric Xu, the Co-founder of Baidu.com. Dr. Tong received his PhD in Biochemistry and Molecular Biology from Institute of Biophysics of Chinese Academy of Science, a BS degree in Life Science from University of Science and Technology of China and the second BS degree in Economics from Peking University.
Wei Xu
Mr. Wei Xu is a Partner at Decheng Capital and has been with the firm since 2017. He is currently serving on the boards of Accuragen, AnHeart Therapeutics, Centricity Vision, Ketai Medical, MDCO and Mynosys.
At Decheng, Mr. Xu focuses on investments in biotechnology and medical device companies in China and US. Prior to joining Decheng, Mr. Xu was Managing Director of Denlux Capital and served on the boards of Cirina (acquired by GRAIL), BEST (NYSE: BSTI), and SINOMED (688108.CH). His investment portfolio also includes Shengda (002259.SZ), SCYAHUA (002497.SZ), Dadifengyuan (acquired by Yonker, 300187.SZ), SZJECH (acquired by Orient Scape, 002310.SZ), NCM China (acquired by Tencent), Hsyuntai, Baoji Clinic, Immune-Onc., etc.
Mr. Xu received his Masters degree in Economics from University of Oslo, and a BS degree in College of Biomedical Engineering & Instrument Science from Zhejiang University.
Zhengwei Zhu
Zhengwei currently serves as Sr. Managing Director of China Merchants Capital Investment Co., Ltd., and head of China Merchants Capital fund of funds. Zhengwei used to serve as Vice President of China Merchants Bank Sydney Branch, and assistant general manager, department of Risk Management of the head office at China Merchants Bank.
Ting Jia, Ph.D.
Dr. Ting Jia, Ph.D., also known as TJ, is the Founder of Octagon Capital Advisors LP and has served as the firm’s Chief Investment Officer since 2019. Prior to founding Octagon Capital, TJ served as Managing Director at Hillhouse Capital Management. Before this, TJ was an investment analyst at BVF Partners and a management consultant at McKinsey’s New York office. TJ started his career as a research fellow at Memorial Sloan-Kettering Cancer Center. He received his Ph.D. in Immunology from Cornell University Weill Medical College and a B.S. with first honor in Biological Sciences from Sun Yat-sen University.
Junyuan Jerry Wang, Ph.D.
CEO & Co-Founder
Dr. Junyuan (Jerry) Wang is Chief Executive Officer & Co-Founder at AnHeart Therapeutics. He has more than 20 years of leadership experience in global clinical development and medical research, having previously worked at Merck Serono, BMS, Wyeth/Pfizer, The Medicines Company, and Merck & Co. He has broad drug development experience across multiple therapeutic areas including oncology, cardiovascular, neuroscience, and immunology. He has made key contributions to successful NDA of Bosulif and Eliquis, and the latter became multi-billion blockbuster drug. He has extensive experience with global health authorities including FDA, EMA, PMDA and NMPA. He also served in leadership roles for professional societies and on the programming committee of leading scientific conferences. Dr. Wang earned his B.S. from the University of Science and Technology of China and Ph.D. in Statistics from Iowa State of University.
Bing Yan, M.D., MBA
Co-Founder & Chief Medical Officer
Dr. Bing Yan is Chief Medical Officer and Co-Founder at AnHeart Therapeutics. He was trained as a medical doctor and has more than 20 years of pharmaceutical industry experience in novel drug and vaccine development, regulatory interactions, and post-approval activities. Prior to joining AnHeart, Dr. Yan was the Global Vice-President and Head of Asia Pacific Clinical Research at Pfizer. He has deep experience across multiple therapeutic areas including neuroscience, vaccines, anti-infectives, transplant, oncology, men’s/women’s health and metabolic disorders. He played a significant leadership role in bringing Prevnar13, Xalkori, Lyrica, Enbrel, Pristiq, Effexor, and Xyntha new drug registrations in China and Japan. Dr. Yan holds a doctorate in clinical medicine from Shanghai JiaoTong University Medical School/Ruijin Hospital and conducted his post-doc fellowship at Johns Hopkins University School of Medicine and Eastern Virginia Medical School.
Lihua Zheng, J.D., Ph.D.
Co-Founder & Chief Business Officer
Dr. Lihua Zheng is Chief Business Officer and Co-Founder at AnHeart Therapeutics. Dr. Zheng leads business development, corporate and financing strategy for the company. He led the successful in-licensing of three clinical-stage oncology assets from Daiichi Sankyo, and also established commercial partnerships with Innovent Biologics and NewG labs with upfront and milestone payments totaling approximately $200 million plus double-digit royalties, and raised more than $100 million in private venture financing. Dr. Zheng was previously a legal and business advisor for biopharma companies at a New York-based international law firm, before he founded a boutique law firm in New York City. He received his J.D. from Fordham University School of Law and a Ph.D. in Molecular and Human Genetics from Baylor College of Medicine. He obtained his Masters and Bachelors of Science degree from Fudan University. He is licensed to practice law in the State of New York.
Scientific Advisory Board
Sai-Hong Ignatius Ou, M.D., Ph.D.
Professor Sai-Hong Ignatius Ou is currently the Health Science Clinical Professor of Medicine in the Department of Medicine, Division of Hematology Oncology at the University of California Irvine School of Medicine. Dr. Ou received his MD and PhD degrees from the University of Texas Southwestern Medical School and completed internship and residency in internal medicine at Duke University Medical Center. Dr. Ou completed his hematology-oncology fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School. Dr. Ou has served as an institutional review committee member for more than 10 years at the University of California Irvine School of Medicine and has been involved in mentoring hematology-oncology fellows and other young investigators globally.
Dr. Ou is one of the eight original phase 1 investigators of crizotinib, and is the senior and corresponding author of the US phase 1 dose escalation of alectinib in the US and participated in the clinical trials of lorlatinib. Dr. Ou has published close to 130 peer-reviewed articles including publication in New England Journal of Medicine, The Lancet Oncology, Journal of Clinical Oncology, JAMA Oncology, and Cancer Discovery. Dr. Ou was on the scientific advisor board of TurningPoint Therapeutics which is developing the fourth generation ALK/ROS1/NTRK inhibitor that can overcome solvent front mutations. His major research interests are in targeted therapy in lung cancer and other solid malignancies that harbors actionable driver mutations in particular receptor tyrosine kinase fusions and the strategies to overcome resistance to tyrosine kinase inhibitors. Dr. Ou serves on the editorial board of Annals of Oncology, Clinical Lung Cancer, and Translational Lung Cancer research and have been ad hoc reviewer for New England Journal of Medicine, The Lancet, The Lancet Oncology and Journal of Clinical Oncology among other journals. Dr. Ou is on the scientific committee for metastatic lung cancer for the American Society of Clinical Oncology annual meeting from 2016-2018.
Caicun Zhou, M.D., Ph.D.
Department of Oncology, Shanghai Pulmonary Hospital, Affiliated to Tongji University School of Medicine, Shanghai, China.
Prof. Dr. Caicun Zhou, PhD, MD, is director of the Department of Oncology, Shanghai Pulmonary Hospital, director of Cancer Institute of Tongji University Medical School, chairman of the Oncology Department of Tongji University. He studied in Japan for two years and was a visiting scientist in USA for half a year. Professor Zhou is a committee member of the Chinese Association of Lung Cancer and the Chinese Society of Clinical Oncology, and is a council member of the Shanghai Anti-cancer Association, the Shanghai Pneumonology Association, and the Shanghai Oncology Association. He serves as a member on the editorial boards of many scientific journals, including ‘Tumor’, ‘Chinese-German Journal of Clinical Oncology’, ‘China Oncology’ and the ‘Chinese Journal of Clinical Oncology’ and also associate editor of Lung Cancer. Professor Zhou was selected as an ‘Excellent learning pioneer’ by the Science and Technology Commission of Shanghai Municipality (STCSM) in 2006, and got grants from the National 863 project and five other key research projects of the STCSM. His major research interests are in customized and targeted therapy of lung cancer, and he has published over 100 papers in scientific journals.
David Ross Camidge, M.D., Ph.D.
Director of Thoracic Oncology, Joyce Zeff Chair in Lung Cancer Research, University of Colorado Cancer Center
Dr. David Ross Camidge is Director of Thoracic Oncology at the University of Colorado. His focus is in Thoracic Malignancies and Developmental Therapeutics (Phase I studies). In 2012, he was announced as the recipient of the 5th Bonnie J. Addario Lectureship as a “Luminary in the quest to eradicate lung cancer.” In 2013, Dr. Camidge became the first physician to receive the Hank Baskett Sr. Spirit Award, for which he was credited as being “one of the leading minds in lung cancer today.” In 2015, he became the inaugural recipient of the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center. Dr. Camidge is also the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium and a member of the National Comprehensive Cancer Network Lung Cancer Committee.
Dr Camidge’s main areas of clinical and research interest are thoracic malignancies and developmental therapeutics. The discoveries he and the Colorado team have made have changed the standard of care for the treatment of lung cancer multiple times. He has authored over 250 academic publications, including in the Journal of Thoracic Oncology, Journal of Clinical Oncology, Lancet Oncology, and New England Journal of Medicine. He has presented his work at numerous national and international meetings.
Following a PhD in Molecular Biology at the Medical Research Council’s Laboratory of Molecular Biology at Cambridge University, UK, Dr Camidge completed his medical training at Oxford University, UK. He then became the first person to double train in Medical Oncology and Clinical Pharmacology in the UK, before joining the University of Colorado.
David A. Reardon, M.D.
David A. Reardon, MD, is a Professor of Medicine at Harvard Medical School and currently serves as Clinical Director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute.
He previously served as the Associate Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke University Medical Center for eleven years. He completed his residency at John Hopkins Hospital in Maryland, USA and was awarded a fellowship at the University of Michigan. Dr. Reardon is an active researcher with special interests in the design and implementation of clinical trials for neuro-oncology and the preclinical evaluation of promising therapeutics for central nervous system tumors.
His work includes using innovative clinical therapeutic agents to improve outcome for patients with brain and spinal tumors, with particular focus on immunotherapeutics. He has also led investigations of molecular-targeting agents, anti-angiogenic reagents, cytotoxins and other biologically-based therapies.
Dr. Reardon has published over 270 peer-reviewed manuscripts. He received the R. Wayne Rundles Award for Excellence in Cancer Research as well as the Award for Excellence in Adult Clinical Research by the Society for Neuro-Oncology in 2015 and 2016. He also served as the tenth president of the Society for Neuro-Oncology from 2013-2015.
Andrés Cervantes, Ph.D.
Dr. Andrés Cervantes is Professor of Medicine at the University of Valencia, Spain. He got his training in Medical Oncology at the University Hospital in Valencia. After completing his clinical training he got a research fellowship for two years at the Free University Hospital in Amsterdam, where he obtained his PhD degree with a work on multidrug resistance in the Cellular Pharmacology Lab of this institution.
Dr. Cervantes serves as Head of the Department of Medical Oncology at the University Hospital in Valencia, Spain. He is also scientific director of the Institute of Health Research INCLIVA, one of the nationally accredited research institutes in Spain. His main areas of research and clinical interest are gastrointestinal and gynaecologic malignancies as well as phase I and early clinical trials and new drug development. He is a dedicated clinical investigator for rectal cancer, a topic in which he has developed several publications concerning the quality of the multidisciplinary teamwork as well as quality assessment of mesorectal surgery, how to improve on the optimal selection of initial therapy and specifically how to approach upper third rectal cancer. He is also responsible of a translational research lab, mainly working in liquid biopsies and in the molecular classification of gastrointestinal malignancies. He is the author of more than two hundred research articles and educational papers published in peer-reviewed journals. He is also one of the Editors in chief of Cancer Treatment Reviews. Since January 2014, he is also Associate Editor for Gastrointestinal Cancer in Annals of Oncology.
Takashi Seto, M.D.
Dr. Seto has over 25 years of experience in oncology research specializing in medical oncology for thoracic malignancies. Conducting clinical trials with new agents has been his primary focus for the past 15 years at the National Kyushu Cancer Center. His tenure also includes Kumamoto Regional Medical Center and Tokai University Hospital. He joined Precision Medicine Asia (PREMIA) in September 2019 to focus on the development of precision medicine and targeted new drug therapies.
Dr. Seto is a member of the International Association for Study of Lung Cancer (IASLC, Board of Directors), the American Society for Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), and the Japan Society of Medical Oncology (JSMO, Councilor), and the Japan Lung Cancer Society (JLCS, Councilor). In 2005, Dr. Seto was involved with the revision of the JLCS Practice Guideline and from 2014 to 2018, served as Chief of Medical Oncology and Multidisciplinary Therapy. He is also an active member of the Japan Clinical Oncology Group (JCOG) and a member and board member of the West Japan Oncology Group (WJOG).
Dr. Seto graduated from Kurume University School of Medicine in 1990.
Partners
